662 related articles for article (PubMed ID: 29932006)
1. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Tuchscherer RM; Thompson AM; Trujillo JM
Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
[TBL] [Abstract][Full Text] [Related]
2. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.
Handelsman Y; Wyne K; Cannon A; Shannon M; Schneider D
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S14-S29. PubMed ID: 30156445
[TBL] [Abstract][Full Text] [Related]
3. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
5. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
Meier JJ
Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
Andreadis P; Karagiannis T; Malandris K; Avgerinos I; Liakos A; Manolopoulos A; Bekiari E; Matthews DR; Tsapas A
Diabetes Obes Metab; 2018 Sep; 20(9):2255-2263. PubMed ID: 29756388
[TBL] [Abstract][Full Text] [Related]
8. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
9. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
10. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Karagiannis T; Liakos A; Bekiari E; Athanasiadou E; Paschos P; Vasilakou D; Mainou M; Rika M; Boura P; Matthews DR; Tsapas A
Diabetes Obes Metab; 2015 Nov; 17(11):1065-74. PubMed ID: 26395850
[TBL] [Abstract][Full Text] [Related]
13. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
15. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
Hall S; Isaacs D; Clements JN
Clin Pharmacokinet; 2018 Dec; 57(12):1529-1538. PubMed ID: 29915923
[TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide in type 2 diabetes.
Anderson SL; Beutel TR; Trujillo JM
J Diabetes Complications; 2020 Apr; 34(4):107520. PubMed ID: 31952996
[TBL] [Abstract][Full Text] [Related]
18. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
20. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
